Journal Article

Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA)

Galloway, Denise A., Magaret, Amalia, Mao, Constance, Stankiewicz Karita, Helen C., Schouten, Jeffrey, Xi, Long Fu, Hauge, Kirsten, Grieco, Verena, Wald, Anna, Madeleine, Margaret M.

2019

Overview

Human papillomavirus (HPV), particularly HPV type 16, causes most anal and vulvar high-grade squamous intraepithelial lesions (HSIL), which are precursors to cancer. After initial treatment of HSIL, more than 30% of patients will have disease recurrence, with even higher recurrence among HIV-positive individuals and men who have sex with men. Recurrences can be debilitating and lead to significant morbidity and medical expense. Observational studies suggest a possible therapeutic benefit of the licensed HPV vaccines in reducing recurrent lesions in previously infected persons. To test whether the licensed prophylactic HPV vaccine (Gardasil-9) can reduce the risk of HSIL recurrence by 50% in previously unvaccinated individuals recently treated for anal or vulvar HSIL. This is a trial protocol for a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial. Eligible participants are aged 27 to 69 at study start and have not received prior HPV vaccination, have had anal or vulvar HSIL diagnosed on or after January 1, 2014, and have no evidence of HSIL recurrence at screening. Persons infected with HIV are eligible for the study provided they are receiving antiretroviral therapy. Target enrollment is 345 individuals. The primary outcome is time to histopathologically confirmed recurrence of HSIL. Differences in the risk for recurrence of HSIL will be evaluated using Cox proportional hazard models. Additional analyses include (1) frequency of HSIL recurrence; (2) role of HPV antibodies in deterring recurrence; (3) role of HPV persistence in recurrence, as measured by HPV genotype or HPV-16 variant lineage determined using swab samples collected at months 0, 18, and 36; and (4) incidence of adverse events. The study will be conducted at the University of Washington Virology Research Clinic from 2017 through 2022. Participants will be followed up for up to 36 months in the clinic, and up to 42 months by telephone. Management of persistent or rapidly recurring anogenital HSIL remains challenging. Results from this study will provide evidence on whether incorporating the nonavalent HPV vaccine into routine care can decrease recurrence of anal and vulvar HSIL. ClinicalTrials.gov identifier: NCT03051516.

• Publisher: American Medical Association
• Subject: Adult / Aged / Anal cancer / Anus / Anus Neoplasms - pathology / Anus Neoplasms - prevention & control / Anus Neoplasms - virology / Colorectal cancer / Double-Blind Method / Female / HIV / HIV Infections - complications / HIV Infections - immunology / HIV Infections - virology / Homosexuality, Male / Human immunodeficiency virus / Human papillomavirus / Human papillomavirus 16 - immunology / Humans / Infectious Diseases / Male / Middle Aged / Neoplasm Recurrence, Local - immunology / Neoplasm Recurrence, Local - pathology / Neoplasm Recurrence, Local - prevention & control / Online Only / Original Investigation / Papillomaviridae - drug effects / Papillomaviridae - genetics / Papillomavirus Infections - complications / Papillomavirus Infections - immunology / Papillomavirus Infections - virology / Papillomavirus Vaccines - therapeutic use / Placebos - administration & dosage / Randomized Controlled Trials as Topic / Risk Factors / Squamous Intraepithelial Lesions - pathology / Vaccines / Vulvar Neoplasms - pathology / Vulvar Neoplasms - prevention & control / Vulvar Neoplasms - virology